Background: Variability of blood pressure (BP) across outpatient visits is frequently dismissed as random fluctuation around a patient's underlying BP.
T
he prognostic value of blood pressure (BP) is mainly based on measurements obtained in a clinical setting, typically from a few visits (1) . Until recently, variability of BP across outpatient visits was dismissed as random fluctuation around a patient's true underlying BP (2, 3) . Although some studies have reported associations between higher visit-to-visit variability (VVV) of systolic BP (SBP) and an increased risk for stroke and coronary heart disease (CHD), other analyses have failed to show such associations (4 -10).
The method applied in estimating VVV of BP varied widely across previous studies. In addition, studies have used as few as 3 visits and as many as 56 visits to estimate the VVV of BP, and the time between visits has ranged from 2 days to as long as 4 years (5, 11, 12). These factors not only influence VVV of BP but could also affect the strength of its association with cardiovascular disease (CVD) outcomes (4, 13).
To address the inconsistent findings from previous studies, we did a secondary data analysis of ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) to examine whether VVV of BP is associated with CVD and mortality events. ALLHAT provides the opportunity to evaluate the association between VVV of BP and major clinical outcomes in a large and diverse population with hypertension in which visits were conducted at set time intervals, BP was measured by following a standardized protocol, and outcomes were evaluated over several years of follow-up.
Lung, and Blood Institute of the National Institutes of Health. A complete description of the rationale and design of ALLHAT has been previously published (14) . In brief, ALLHAT was designed to determine whether treatment initiated with a calcium-channel blocker (amlodipine), angiotensin-converting enzyme inhibitor (lisinopril), or ␣-blocker (doxazosin)-each compared with treatment initiated with a diuretic (chlorthalidone)-would lower major cardiovascular outcomes. The primary end point was incidence of fatal CHD or nonfatal MI. A total of 42 418 hypertensive adults aged 55 years or older with 1 or more additional risk factor for CVD were enrolled at 623 clinical sites across the United States, Canada, Puerto Rico, and the U.S. Virgin Islands between February 1994 and January 1998. The doxazosin treatment group was discontinued in 2000 because of the small chance of finding a benefit on CHD outcomes and an increased risk for CVD than in the chlorthalidone group (15). The main results comparing participants randomly assigned to chlorthalidone, amlodipine, or lisinopril were published in December 2002 (16). The trial was approved by local institutional review boards, and all participants provided written informed consent. Our current analysis was approved by the Institutional Review Board at the University of Alabama at Birmingham.
Study Visits, BP Measurements, and Calculation of VVV of BP
To calculate intraindividual VVV of SBP and diastolic BP (DBP), we used data from 7 follow-up visits that occurred 6, 9, 12, 16, 20, 24, and 28 months after randomization. We chose to begin the assessment period at the 6-month follow-up visit to avoid confounding by the initial reduction in BP that occurred between randomization and this visit (SBP, 6 to 10 mm Hg; DBP, approximately 5 mm Hg) due to early medication titration. To increase the precision of estimates, we calculated VVV of BP for participants with BP measurements at 5, 6, or 7 visits conducted between month 6 and 28 after randomization. The VVV of BP was imputed for participants who attended fewer than 5 visits between months 6 and 28. To maximize follow-up time, we did not extend the assessment past the 28-month follow-up visit. At each follow-up visit, BP was measured twice by a trained observer by means of a standardized technique (17). Using the average BP at each visit, we defined VVV of BP by the intraindividual SD across visits. Average real variability (ARV) and SD independent of the mean (SDIM) were calculated as alternative metrics for VVV of BP (Appendix Figure, available at www .annals.org) (18). The VVV of DBP was also calculated in secondary analyses.
Outcome Ascertainment
We studied 4 outcomes, including fatal CHD or nonfatal MI, all-cause mortality, stroke, and heart failure. The event ascertainment process is detailed elsewhere (14, 16). Participants were followed from the end of the assessment period to the date of each outcome, their date of death, or the end of active ALLHAT follow-up (1 October 2001 through 31 March 2002).
Covariate Information
Covariates used for adjustment were selected a priori on the basis of their potential role as confounders. Baseline (before randomization) variables included age, sex, race/ethnicity, education, current cigarette smoking status, body mass index, use of aspirin, highdensity lipoprotein cholesterol level less than 0.91 mmol/L (<35 mg/dL) (at ≥2 occasions in the 5 years before ALLHAT enrollment), total cholesterol level, estimated glomerular filtration rate (eGFR), diabetes, history of MI or stroke, documentation of other atherosclerotic CVD, history of revascularization, atrial fibrillation by electrocardiography, left ventricular hypertrophy (LVH), the presence of ST depression and T-wave inversion, and use of antihypertensive medication before ALLHAT randomization. The eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation (19) . Data collected at visits conducted 6 to 28 months after randomization were used to calculate mean SBP and DBP; pulse pressure; the use of antihypertensive medications beyond the randomization drug; changes in antihypertensive medication regimen (adding, stopping, or changing antihypertensive medications); use of statins; and low adherence, which is defined as a report of a participant receiving less than 80% of the randomization drug at any visit between months 6 and 28. Participants who reported taking 80% or more of their randomization drug at every visit between months 6 and 28 were considered to have high adherence.
Statistical Analysis
Because of limited follow-up available after the assessment period for participants randomly assigned to receive doxazosin, we restricted our analyses to the 33 357 ALLHAT participants randomly assigned to receive chlorthalidone, amlodipine, or lisinopril. We excluded 7543 participants who had CVD events or died
EDITORS' NOTES Context
It is not clear whether variability in a patient's outpatient blood pressure (BP) measurements has prognostic importance.
Contribution
Patients with greater visit-to-visit variability in BP readings had an increased risk for cardiovascular events and mortality, which was independent of their overall degree of BP control.
Implication
Further studies are warranted to assess whether reducing visit-to-visit BP variations will alter the risk for adverse cardiovascular outcomes.
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Visit-to-Visit Variability of BP on CVD and Mortality Outcomes before the 28-month visit. We imputed VVV of BP for participants with fewer than 5 visits and BP measurements between months 6 and 28 of follow-up. In addition, missing data for covariates were imputed (Appendix Table 1 , available at www.annals.org). Imputation was performed with 10 data sets using chained equations.
Characteristics of participants included in the current analyses were calculated after participants were stratified into a quintile of SD of SBP. The Kaplan-Meier method was used to calculate the cumulative incidence of each outcome by quintile of SD of SBP. Cox proportional hazards regression was used to calculate multivariable-adjusted hazard ratios (HRs) for each outcome associated with a quintile of SD of SBP, with the lowest quintile serving as the reference. Four nested models were constructed. Model 1 included adjustment for age, race/ethnicity, sex, region of residence, and antihypertensive randomization assignment. Model 2 includes the variables in model 1 and additional adjustment for education, smoking status, body mass index, use of aspirin, low high-density lipoprotein cholesterol level, total cholesterol level, eGFR, diabetes, history of MI or stroke, history of other atherosclerotic CVD, history of coronary revascularization, atrial fibrillation by electrocardiography, major ST depression or T-wave inversion, LVH, use of antihypertensive medications before ALLHAT randomization, and statin use during the assessment period (months 6 through 28 of follow-up). Model 3 includes the variables in model 2 and additional adjustment for mean pulse pressure, medication adherence, use of antihypertensive medications beyond the randomized drug, and changes in antihypertensive medication regimen-all of which occurred during the assessment period (months 6 through 28 of follow-up). Model 4 includes the variables in model 3 and additional adjustment for mean SBP across the visits used to calculate VVV of SBP. Trends across quintiles were calculated by modeling the quintile of SD of SBP as an ordinal variable. We repeated these analyses for the ARV and SDIM of SBP and VVV of DBP using SD, ARV, and SDIM in a complete case analyses (that is, analyses without multiple imputation).
Next, we calculated fully adjusted (model 4) HRs for the highest versus lowest quintile of SD of SBP for each outcome stratified by age (<65 and ≥65 years), sex, race (black and nonblack persons), diabetes status, antihypertensive medication adherence, BP control (defined as a mean SBP and DBP <140/90 mm Hg across visits from 6 to 28 months after randomization [uncontrolled BP was defined as a mean SBP and DBP ≥140/90 mm Hg]), LVH, history of CVD, and antihypertensive randomization assignment; further, we tested for multiplicative interactions between these groups. Finally, the multivariable-adjusted HRs for each outcome associated with the SD of SBP, modeled as a continuous variable, were calculated using restricted quadratic splines. All analyses were done in Stata, version 13.0 (Stata Corp).
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RESULTS
Characteristics of study participants included in the current analysis by quintile of SD of SBP are presented in Table 1 . Older and non-Hispanic black persons were associated with being in a higher quintile of SD of SBP, whereas men were more likely to be in the lower quintiles of SD of SBP. Participants with higher SD of SBP had less education, were less likely to be receiving aspirin and have a low high-density lipoprotein cholesterol level, had a higher total cholesterol level and lower eGFR, and were more likely to have major ST depression or T-wave inversion or LVH by electrocardiography. Use of antihypertensive medication before baseline was more common at higher SD of SBP. Higher mean SBP, DBP, and pulse pressure were associated with higher SD of SBP. In addition, persons with Visit-to-visit BP assessment period (7 visits with SBP and DBP measured)
End of follow-up
Outcome ascertainment* Months after baseline ALLHAT = Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; BP = blood pressure; DBP = diastolic blood pressure; SBP = systolic blood pressure; VVV = visit-to-visit variability. * Participants were followed for a mean of 2.7 to 2.9 y (maximum, 5.7 y) depending on the outcome after assessment of VVV of BP.
Visit-to-Visit Variability of BP on CVD and Mortality Outcomes ORIGINAL RESEARCH higher SD of SBP were more likely to have low adherence and to change medication classes. Participants randomly assigned to receive chlorthalidone and amlodipine were less likely, whereas those randomly assigned to receive lisinopril were more likely, to be in the highest quintiles of SD of SBP.
After the assessment period, 1194 cases of fatal CHD or nonfatal MI, 1948 deaths, 606 strokes, and 921 cases of heart failure occurred over a mean follow-up of 2.7 to 2.9 years (maximum, 5.7 years). Incidence of each outcome was progressively higher at higher levels of SD of SBP ( Figure 2 and Table 2 ). After full multivariable adjustment, participants in the highest versus lowest quintile of SD of SBP had a statistically significantly higher risk for fatal CHD or nonfatal MI, mortality, and stroke; further, the HR for heart failure comparing the highest and lowest quintile of SD of SBP was 1.25 (95% CI, 0.97 to 1.61). Results were consistent when modeling VVV of SBP using ARV and SDIM (Appendix Tables 2 and 3, available at www.annals.org) in analyses without multiple imputation (Appendix Table 4 , available at www.annals.org) and for VVV of DBP (Appendix Tables 5 to 8, available at www.annals.org).
The association between SD of SBP and outcomes were consistent across subgroups defined by age, sex, race, diabetes status, antihypertensive medication adherence, BP control, LVH, history of CVD, and randomization assignment with 2 exceptions (Figure 3) . The ALLHAT = Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ASCVD = atherosclerotic cardiovascular disease; BMI = body mass index; BP = blood pressure; DBP = diastolic blood pressure; eGFR = estimated glomerular filtration rate; HDL = high-density lipoprotein; LVH = left ventricular hypertrophy; MI = myocardial infarction; SBP = systolic blood pressure. * Assessed using data from visits done 6 -28 mo after randomization in ALLHAT. † <0.91 mmol/L (<35 mg/dL). ‡ Visits conducted 6 -28 mo after ALLHAT randomization.
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Visit-to-Visit Variability of BP on CVD and Mortality Outcomes highest versus lowest quintile of SD of SBP was associated with all-cause mortality for participants without LVH (interaction P = 0.016). Further, no association was present between the highest versus lowest quintile of SD of SBP and the stroke risk for participants randomly assigned to lisinopril or amlodipine; however, the highest quintile of SD of SBP was associated with an increased risk for stroke in participants randomly assigned to chlorthalidone (interaction P = 0.083 [comparing the lisinopril and chlorthalidone subgroups]). The association between the SD of SBP, modeled as a continuous variable, and fatal CHD or nonfatal MI was J-shaped, with the risk being lowest at an SD of SBP of approximately 6 mm Hg (Figure 4) . A graded association was present between a higher SD of SBP and an increased risk for all-cause mortality, stroke, and heart failure.
DISCUSSION
In this secondary analysis of ALLHAT, we showed strong associations between VVV of SBP and fatal CHD or nonfatal MI, all-cause mortality, stroke, and heart failure. These associations were present after multivariable adjustment and were consistent across several subgroups and when modeling VVV of SBP as a continuous variable. A statistically significant association was also present between VVV of DBP and the aforementioned outcomes. These data add to the growing body of evidence on the prognostic value of VVV of BP as a CVD risk factor.
In 2010, Rothwell and colleagues (4) published a comprehensive series of analyses from 4 studies showing strong associations between VVV of BP and the risk for stroke and CHD (4). For example, when comparing the highest and lowest decile of SD of SBP, the multivariable-adjusted HR for stroke Visit-to-Visit Variability of BP on CVD and Mortality Outcomes ORIGINAL RESEARCH also associated with an increased risk for CHD and stroke in these studies. Over the past 4 years, many trials have found conflicting results when evaluating the associations between VVV of BP and outcomes (5, 6, 20 -23). Heterogeneity of the study designs may have contributed to the conflicting results. For example, prior studies have varied widely with respect to the number of visits used to calculate VVV of BP, time between visits, and study populations enrolled. Some studies relied on only 3 visits to define VVV of BP, and the time between visits ranged from days to years across studies (5, 24 -26). Using data from TROPHY (Trial of Preventing Hypertension), Levitan and colleagues (13) found that the number of visits and time between visits affect VVV of SBP. Given the large sample size, frequent monitoring of BP at set time intervals, and long follow-up in ALLHAT, we were able to overcome many of the limitations in prior analyses.
The association between VVV of BP and the 4 outcomes was consistent for ALLHAT participants randomly assigned to chlorthalidone, amlodipine, or lisinopril. However, an association between higher VVV of BP and increased risk for stroke was present for participants randomly assigned to chlorthalidone but not lisinopril or amlodipine. Given the number of compari- CHD = coronary heart disease; HR = hazard ratio; MI = myocardial infarction; SBP = systolic blood pressure. * Per 1000 person-years. † Includes adjustment for age, sex, race/ethnicity, region of residence, and randomization assignment. ‡ Includes variables in model 1 and additional adjustment for smoking status, body mass index, estimated glomerular filtration rate, diabetes, total cholesterol levels, history of MI or stroke, history of coronary revascularization, atrial fibrillation by electrocardiography, history of other atherosclerotic cardiovascular disease, major ST depression or T-wave inversion, left ventricular hypertrophy, low high-density lipoprotein cholesterol levels, aspirin use, statin use, use of blood pressure medications before study randomization, and years of education. § Includes variables in model 2 and additional adjustment for pulse pressure, medication adherence, classes of antihypertensive medication being received, and changes in classes of antihypertensive medication being received.
͉͉ Includes variables in model 3 and additional adjustment for mean SBP.
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Visit-to-Visit Variability of BP on CVD and Mortality Outcomes Data were adjusted for age, sex, race/ethnicity, region of residence, randomization assignment, smoking status, body mass index, estimated glomerular filtration rate, diabetes, total cholesterol level, history of MI or stroke, history of coronary revascularization, atrial fibrillation by electrocardiography, history of other atherosclerotic CVD, major ST depression or T-wave inversion, LVH, low high-density lipoprotein cholesterol level, aspirin use, use of BP medications before study randomization, statin use, pulse pressure, medication adherence, antihypertensive medication classes being received, changes in antihypertensive medication classes being received, and mean systolic BP. Further, BP control was defined as systolic or diastolic BP less than 140/90 mm Hg. All interaction P values were greater than 0.10 for each subgroup and outcome except when comparing LVH on all-cause mortality (interaction P = 0.016) and lisinopril versus chlorthalidone on stroke (interaction P = 0.083). ALLHAT = Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; BP = blood pressure; CHD = coronary heart disease; CVD = cardiovascular disease; HR = hazard ratio; LVH = left ventricular hypertrophy; MI = myocardial infarction.
Visit-to-Visit Variability of BP on CVD and Mortality Outcomes ORIGINAL RESEARCH sons in the subgroup analyses, this finding may be due to chance. Additional studies are needed to confirm this finding and further investigate whether certain drug classes attenuate the effect of VVV of BP on cardiovascular outcomes. We note the potential utility of clarifying the prognostic value of VVV of BP among hypertensive persons. Although antihypertensive treatment reduces the risk for mortality and CVD outcomes, hypertensive persons with controlled BP continue to have measureable excess risk (27, 28). Novel therapies or drug combinations addressing VVV of BP might further reduce this excess risk. Studies of the association between VVV of BP and CVD outcomes may also help in understanding the mechanistic links between hypertension and CVD, which can lead to more efficacious therapy.
Low medication adherence has been proposed as a mechanism underlying the increased risk for CVD at higher levels of VVV of BP (29). In a prior study, Muntner and colleagues (30) found that only a small percentage of VVV of BP could be explained by low medication adherence. Further, higher VVV of SBP was associated with an increased risk for stroke among persons with high adherence in ASCOT-BPLA (4). In the current study, we found an association of higher CVD and mortality risk at higher VVV of BP after we adjusted for medication adherence and in analyses restricted to participants with high adherence at every study visit. Taken together, these data suggest that medication adherence does not explain the association between VVV of SBP and outcomes.
Arterial stiffness, endothelial dysfunction, and subclinical inflammation have been proposed as mechanisms underlying the association between VVV of BP and outcomes (28 -33). Shimbo and colleagues (31) found that higher levels of VVV of SBP were associated with lower aortic distensibility found on magnetic resonance imaging and lower large and small artery elasticity found by pulse contour analysis. Further, Nagai and colleagues (32) reported an association between com- The solid black line in each figure represents the HR, and the green shaded area represents the 95% CI. The histogram represents the distribution of SD of SBP in the ALLHAT population. Data were adjusted for age, sex, race/ethnicity, region of residence, randomization assignment, smoking status, body mass index, estimated glomerular filtration rate, diabetes, total cholesterol level, history of MI or stroke, history of coronary revascularization, atrial fibrillation by electrocardiography, history of other atherosclerotic cardiovascular disease, major ST depression or T-wave inversion, left ventricular hypertrophy, low high-density lipoprotein cholesterol level, aspirin use, use of blood pressure medications before study randomization, statin use, pulse pressure, medication adherence, antihypertensive medication classes being received changes in antihypertensive medication classes being received and mean SBP. ALLHAT = Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; CHD = coronary heart disease; HR = hazard ratio; MI = myocardial infarction; SBP = systolic blood pressure.
Visit-to-Visit Variability of BP on CVD and Mortality Outcomes mon carotid artery stiffness and VVV of BP. Diaz and colleagues (33) found decreased endothelial function to be associated with higher VVV of BP. We are not aware of formal studies of the association between VVV of BP and subclinical inflammation. Studies aimed at better understanding the reasons for high VVV of BP may provide useful information for reducing CVD risk.
The strengths of using ALLHAT data to study the association between VVV of BP and outcomes include a large sample size of white, black, and Hispanic persons. Blood pressure was measured in ALLHAT following a standardized protocol during visits at set time points. For outcomes reported here, events were ascertained and diagnoses were assigned by following a standardized protocol. Additional strengths of ALLHAT include its collection of information on many potential confounders. The association between higher VVV of BP and outcomes after multivariable adjustment for these variables is noteworthy. Further, there are known and potential limitations associated with the current analysis. We present a post hoc analysis of ALLHAT using an observational study design. Therefore, causality cannot be determined. In addition, ALLHAT is a communityand practice-based randomized clinical trial, which may limit the generalizability of the current analysis. Although outcomes were collected and ascertained by following a standardized protocol, given the size of ALLHAT adjudication by a blinded committee did not occur for all events. Approximately 22% of ALLHAT participants did not have 5 or more BP measurements during the assessment period. For these participants, we imputed their VVV of BP. Of note, many patients changed antihypertensive medications during the assessment period, which could affect the associations we report. Although we conducted statistical adjustment for regimen changes, residual confounding may remain. Low adherence was defined through selfreport, and more robust information was not available.
In this secondary analysis of ALLHAT, higher VVV of SBP and DBP were associated with an increased risk for CVD and all-cause mortality. The current study adds to the growing body of evidence on the prognostic importance of VVV of BP as a CVD risk factor. Future studies are needed to identify the mechanisms underlying the association between high VVV of BP and the risk for CVD and mortality and to determine whether lowering VVV of BP reduces this risk. Financial Support: By the National Heart, Lung, and Blood Institute of the National Institutes of Health (contracts NO1-HC-35130 and HHSN268201100036C and award R01 HL110993); further, the ALLHAT investigators acknowledge study medications contributed by Pfizer (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and BristolMyers Squibb (pravastatin) and financial support from Pfizer. 11.6 (9.8-13.4) 11.4 (9.6-13.2) 13.9 (11.9-15.9) 17.8 ( CHD = coronary heart disease; HR = hazard ratio; MI = myocardial infarction; SBP = systolic blood pressure; SDIM = SD independent of the mean. * Per 1000 person-years. † Includes adjustment for age, sex, race/ethnicity, region of residence, and randomization assignment. ‡ Includes variables in model 1 and additional adjustment for smoking status, body mass index, estimated glomerular filtration rate, diabetes, total cholesterol levels, history of MI or stroke, history of coronary revascularization, atrial fibrillation by electrocardiography, history of other atherosclerotic cardiovascular disease, major ST depression or T-wave inversion, left ventricular hypertrophy, low high-density lipoprotein cholesterol levels, aspirin use, statin use, use of blood pressure medications before study randomization, and years of education. § Includes variables in model 2 and additional adjustment for pulse pressure, medication adherence, classes of antihypertensive medication being received, and changes in classes of antihypertensive medication being received. ͉͉ Includes variables in model 3 and additional adjustment for mean SBP. CHD = coronary heart disease; DBP = diastolic blood pressure; HR = hazard ratio; MI = myocardial infarction; SDIM = SD independent of the mean. * Per 1000 person-years. † Includes adjustment for age, sex, race/ethnicity, region of residence, and randomization assignment. ‡ Includes variables in model 1 and additional adjustment for smoking status, body mass index, estimated glomerular filtration rate, diabetes, total cholesterol levels, history of MI or stroke, history of coronary revascularization, atrial fibrillation by electrocardiography, history of other atherosclerotic cardiovascular disease, major ST depression or T-wave inversion, left ventricular hypertrophy, low high-density lipoprotein cholesterol levels, aspirin use, statin use, use of blood pressure medications before study randomization, and years of education. § Includes variables in model 2 and additional adjustment for pulse pressure, medication adherence, classes of antihypertensive medication being received, and changes classes of antihypertensive medication being received. ͉͉ Includes variables in model 3 and additional adjustment for mean DBP. 6.5 (5.0-7.9) 8.3 (6.7-10.0) 9.7 (7.9-11.5) 9.4 (7.6-11.1) 11.5 (9.5-13. CHD = coronary heart disease; DBP = diastolic blood pressure; HR = hazard ratio; MI = myocardial infarction. * Per 1000 person-years. † Includes adjustment for age, sex, race/ethnicity, region of residence, and randomization assignment. ‡ Includes variables in model 1 and additional adjustment for smoking status, body mass index, estimated glomerular filtration rate, diabetes, total cholesterol levels, history of MI or stroke, history of coronary revascularization, atrial fibrillation by electrocardiography, history of other atherosclerotic cardiovascular disease, major ST depression or T-wave inversion, left ventricular hypertrophy, low high-density lipoprotein cholesterol levels, aspirin use, statin use, use of blood pressure medications before study randomization, and years of education. § Includes variables in model 2 and additional adjustment for pulse pressure, medication adherence, classes of antihypertensive medication being received, and changes in classes of antihypertensive medication being received. ͉͉ Includes variables in model 3 and additional adjustment for mean DBP.
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